We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Instem Plc | LSE:INS | London | Ordinary Share | GB00B3TQCK30 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 830.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMINS
RNS Number : 6343E
Instem plc
09 May 2017
Instem plc
("Instem" or the "Company")
Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that, following the exercise of share options by an employee, 5,154 ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.
Application will be made to the London Stock Exchange for the admission of the 5,154 new Ordinary Shares to trading on AIM and admission is expected to take place at 8.00 a.m. on 15 May 2017.
Total Voting Rights
Following the issue and allotment of the above new Ordinary Shares, the Company's issued share capital comprises 15,776,552 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 15,776,552.
The figure of 15,776,552 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Instem plc +44 (0) 1785 825 600 Phil Reason, CEO Nigel Goldsmith, CFO N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000 Richard Lindley Nick Owen James White Walbrook Financial PR +44 (0) 20 7933 8780 Paul Cornelius instem@walbrookpr.com Helen Cresswell Sam Allen Paul Whittington
About Instem
Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEADSNEALXEFF
(END) Dow Jones Newswires
May 09, 2017 09:25 ET (13:25 GMT)
1 Year Instem Chart |
1 Month Instem Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
